We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Asks How Far Eagle’s Bendeka Exclusivity Should Extend
FDA Asks How Far Eagle’s Bendeka Exclusivity Should Extend
The FDA has invited applicants for certain products containing bendamustine to share how broad of a scope they believe Eagle Pharmaceuticals’ seven-year orphan drug exclusivity for Bendeka (bendamustine) should be, and if it should apply to Treanda.